Andreas Kogelnik

Andreas M. Kogelnik, ("Andy") MD, PhD., is an Internal Medicine and Infectious Diseases specialist, the director of the Open Medicine Institute, Mountain View, California, USA, and a member of the Scientific Advisory Board for the Open Medicine Foundation, Agoura Hills, CA. His interests are in the bioinformatics and genomic revolution in medicine and is committed to the study of and treatment of ME/CFS and other chronic illnesses.

Education

 * MD from Emory University
 * PhD in bioengineering from Georgia Tech
 * Residency in Internal Medicine at Stanford University
 * Fellowship in Infectious Diseases at Stanford University

Research Publications on ME/CFS

 * 2013, Randomized clinical trial to evaluate the efficacy and safety of valganciclovir in a subset of patients with chronic fatigue syndrome.
 * 2011, No evidence of murine-like gammaretroviruses in CFS patients previously identified as XMRV-infected.
 * 2006, Use of valganciclovir in patients with elevated antibody titers against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) who were experiencing central nervous system dysfunction including long-standing fatigue.

Articles

 * 2014, Comments on Progressive Research Year of 2014

Talks and Interviews

 * 2014, Youtube - What Works For Chronic Fatigue Syndrome
 * 2014, 9th Invest in ME International ME Conference 2014 - No title of talk given
 * 2014, Episode 56: Dr. Andreas Kogelnik on the "Real Thrust" of ME/CFS Research
 * 2014, [[MECFS Alert] Episode 55: Interview with Dr. Andreas Kogelnik]
 * 2013, 8th Invest in ME International ME Conference 2013 - Key Note Speech: Strategies for ME Research and Collaboration
 * 2012, [[MECFS Alert] Episode 23: The Open Medicine Institute, Part 1], [[MECFS Alert] Episode 23: The Open Medicine Institute, Part 2], and [[MECFS Alert] Episode 23: The Open Medicine Institute, Part 3]
 * 2012, [[MECFS Alert] Episode 22: Interview with Dr. Andreas Kogelnik, Part 1] and [[MECFS Alert] Episode 22: Interview with Dr. Andreas Kogelnik, Part 2]
 * 2012, 7th Invest in ME International ME Conference 2012 - Strategies for ME Research and Collaboration